Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Bitcoin Well (V.BTCW) Reports Q1 2024 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

Business Wire May 20, 2022

Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)

Business Wire May 10, 2022

Merck to Participate in Bank of America Securities 2022 Healthcare Conference

Business Wire May 4, 2022

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

Business Wire April 29, 2022

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

Business Wire April 29, 2022

Merck Announces First-Quarter 2022 Financial Results

Business Wire April 28, 2022

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Business Wire April 25, 2022

Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022

Business Wire April 20, 2022

Health Canada Approves KEYTRUDA® (pembrolizumab) for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery

Canada NewsWire April 18, 2022

Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company's Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

Business Wire April 14, 2022

Health Canada Approves GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the Prevention of Oropharyngeal and Other Head and Neck Cancers

Canada NewsWire April 11, 2022

Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28

Business Wire April 8, 2022

Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need

Business Wire April 5, 2022

Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck's HPV Vaccine Supply and Support Broader and Equitable Access

Business Wire April 4, 2022

Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE(TM) (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children

Business Wire April 1, 2022

Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO(TM) (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

Business Wire April 1, 2022

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer

Business Wire March 25, 2022

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

Business Wire March 25, 2022

Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer

Business Wire March 23, 2022

Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS(TM) in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT

Business Wire March 22, 2022